Funding

Semarion

United Kingdom · Biotech · Healthtech

Develops next-generation cell assay technology for drug discovery

Visit semarion.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Undisclosed$3.8MCambridge Capital Group — Role not disclosedCambridge Enterprise Ventures — Role not disclosedFound Capital — Role not disclosedOxford Innovation Finance — Role not disclosedParkwalk — Role not disclosedStart Codon — Role not disclosedThe FSE Group — Role not disclosed

Investors

Cambridge Capital GroupUndisclosedCambridge Enterprise VenturesUndisclosedFound CapitalUndisclosedOxford Innovation FinanceUndisclosedParkwalkUndisclosedStart CodonUndisclosedThe FSE GroupUndisclosed

Coverage

Mar 31, 2026Semarion · Undisclosed

Similar companies

Guoke Brain-ComputerBeijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.Undisclosed · Seed
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
Sourcessemarion.com ↗